Availability and costs of medicines for the treatment of tuberculosis in Europe

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F23%3A10001187" target="_blank" >RIV/00064190:_____/23:10001187 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(22)00394-9/fulltext" target="_blank" >https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(22)00394-9/fulltext</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.cmi.2022.07.026" target="_blank" >10.1016/j.cmi.2022.07.026</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Availability and costs of medicines for the treatment of tuberculosis in Europe

Popis výsledku v původním jazyce

Objectives: To evaluate the access to comprehensive diagnostics and novel antituberculosis medicines in European countries. Methods: We investigated the access to genotypic and phenotypic Mycobacterium tuberculosis drug susceptibility testing and the availability of antituberculosis drugs and calculated the cost of drugs and treatment regimens at major tuberculosis treatment centres in countries of the WHO European region where rates of drug-resistant tuberculosis are the highest among all WHO regions. Results were stratified by middle-income and high-income countries. Results: Overall, 43 treatment centres from 43 countries participated in the study. For WHO group A drugs, the frequency of countries with the availability of phenotypic drug susceptibility testing was as follows: (a) 75% (30/40) for levofloxacin, (b) 82% (33/40) for moxifloxacin, (c) 48% (19/40) for bedaquiline, and (d) 72% (29/40) for linezolid. Overall, of the 43 countries, 36 (84%) and 24 (56%) countries had access to bedaquiline and delamanid, respectively, whereas only 6 (14%) countries had access to rifapentine. The treatment of patients with extensively drug-resistant tuberculosis with a regimen including a carbapenem was available only in 17 (40%) of the 43 countries. The median cost of regimens for drug-susceptible tuberculosis, multidrug-resistant/rifampicin-resistant tuberculosis (shorter regimen, including bedaquiline for 6 months), and extensively drug-resistant tuberculosis (including bedaquiline, delamanid, and a carbapenem) were EUR44 (minimum-maximum, EUR15-152), EUR764 (minimum-maximum, EUR542-15152), and EUR8709 (minimum-maximum, EUR7965-11759) in middle-income countries (n = 12) and EUR280 (minimum-maximum, EUR78-1084), EUR29765 (minimum-maximum, EUR11116-40584), and EUR217591 (minimum-maximum, EUR82827-320146) in high-income countries (n = 29), respectively. Discussion: In countries of the WHO European region, there is a widespread lack of drug susceptibility testing capacity to new and repurposed antituberculosis drugs, lack of access to essential medications in several countries, and a high cost for the treatment of drug-resistant tuberculosis. (C) 2022 The Author(s)

Název v anglickém jazyce

Availability and costs of medicines for the treatment of tuberculosis in Europe

Popis výsledku anglicky

Objectives: To evaluate the access to comprehensive diagnostics and novel antituberculosis medicines in European countries. Methods: We investigated the access to genotypic and phenotypic Mycobacterium tuberculosis drug susceptibility testing and the availability of antituberculosis drugs and calculated the cost of drugs and treatment regimens at major tuberculosis treatment centres in countries of the WHO European region where rates of drug-resistant tuberculosis are the highest among all WHO regions. Results were stratified by middle-income and high-income countries. Results: Overall, 43 treatment centres from 43 countries participated in the study. For WHO group A drugs, the frequency of countries with the availability of phenotypic drug susceptibility testing was as follows: (a) 75% (30/40) for levofloxacin, (b) 82% (33/40) for moxifloxacin, (c) 48% (19/40) for bedaquiline, and (d) 72% (29/40) for linezolid. Overall, of the 43 countries, 36 (84%) and 24 (56%) countries had access to bedaquiline and delamanid, respectively, whereas only 6 (14%) countries had access to rifapentine. The treatment of patients with extensively drug-resistant tuberculosis with a regimen including a carbapenem was available only in 17 (40%) of the 43 countries. The median cost of regimens for drug-susceptible tuberculosis, multidrug-resistant/rifampicin-resistant tuberculosis (shorter regimen, including bedaquiline for 6 months), and extensively drug-resistant tuberculosis (including bedaquiline, delamanid, and a carbapenem) were EUR44 (minimum-maximum, EUR15-152), EUR764 (minimum-maximum, EUR542-15152), and EUR8709 (minimum-maximum, EUR7965-11759) in middle-income countries (n = 12) and EUR280 (minimum-maximum, EUR78-1084), EUR29765 (minimum-maximum, EUR11116-40584), and EUR217591 (minimum-maximum, EUR82827-320146) in high-income countries (n = 29), respectively. Discussion: In countries of the WHO European region, there is a widespread lack of drug susceptibility testing capacity to new and repurposed antituberculosis drugs, lack of access to essential medications in several countries, and a high cost for the treatment of drug-resistant tuberculosis. (C) 2022 The Author(s)

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30303 - Infectious Diseases

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical Microbiology and Infection

ISSN

1198-743X

e-ISSN

1469-0691

Svazek periodika

29

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

8

Strana od-do

77-84

Kód UT WoS článku

000910464500001

EID výsledku v databázi Scopus

2-s2.0-85138577531